Alkermes CEO Says A Small Miss In Sleep-Disorder Trial Wouldn't End Orexin Drug, If Signal Holds
Blair Jackson, in his first call as CEO, said Alkermes would adjust its pricing once Takeda sets its own within weeks.
Alkermes CEO Blair Jackson said on the company's third-quarter earnings call Tuesday that falling "a little bit short" in the idiopathic hypersomnia trial of its orexin drug alixorexton would not automatically end the program, provided the company sees an appropriate signal. Results from the roughly 130-person study are due around year end or early 2027.
A near-miss is not a stop sign
Asked by a Bank of America analyst what the Vibrance-3 study must show, Jackson said Alkermes wants to hit statistical significance. He added: "If we were to fall a little bit short, does that mean we would stop the program? No." His condition was that Alkermes "have an appropriate signal that trial design would be able to overcome."
He said early once-daily data showed a similar effect size in idiopathic hypersomnia and in narcolepsy type 2. The study also includes the company's first look at split dosing in a hypersomnolence disorder.
An analyst from Deutsche Bank asked about next steps. Jackson said a Phase 3 study would probably be sized like the narcolepsy type 2 trial, with a meeting with the FDA as the rate-limiting step. About 25% of idiopathic hypersomnia patients are long sleepers, he said, a group Alkermes has less experience with.
Pricing waits on Takeda
Takeda's orexin drug is expected to reach the market this month for a subset of narcolepsy type 1 patients. Jackson told an analyst that Takeda would price within weeks, setting the range for the market, and Alkermes has flexibility. "We'll adjust accordingly," he said.
Alkermes develops and sells brain and nervous-system medicines, including the Vivitrol, Aristada and Lybalvi franchises. Its proprietary products are expected to reach net sales of nearly $1.6 billion in 2026, Jackson said, and he called the coming year pivotal, with six orexin studies set to read out.
The quarter behind the pipeline
Net sales of proprietary products rose 31% from a year earlier to $417.3 million, including the sleep drug acquired in a deal that closed in mid-February. Total revenue was $480.1 million, and Chief Financial Officer Joshua Reed reported GAAP net income of $16.3 million and adjusted EBITDA of $120.1 million, with about $787.6 million in cash and investments.
Research spending reached $121.1 million, up from $81.7 million a year earlier. Reed reiterated 2026 expectations and said 2027 cost of goods sold should fall as the inventory step-up fades. Full 2027 guidance comes on the February call.
Other orexin readouts: Phase 3 narcolepsy results begin in mid-2027, and Phase 2 ADHD data are expected in the second half of 2027.
Takeda's price, due within weeks, and Vibrance-3 results around year end or early 2027 are the next markers.
Sources
- Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates — Yahoo Finance
- Alkermes: Q3 Earnings Snapshot — Associated Press
- Alkermes: Q3 Earnings Snapshot – WTOP News — wtop.com
- Alkermes: Q3 Earnings Snapshot | khou.com — Associated Press
- Alkermes: Q3 Earnings Snapshot | 9news.com — Associated Press